Virios Said In Shareholder Letter, We Are Exploring Options To Advance The IMC-2 LC Investigational New Drug Application And Its Proposed Phase 2 Research Program
Virios Said In Shareholder Letter, We Are Exploring Options To Advance The IMC-2 LC Investigational New Drug Application And Its Proposed Phase 2 Research Program
維里奧斯在股東信中表示，我們正在探索推進 IMC-2 LC 研究性新藥申請及其擬議的第二階段研究計劃的備選方案
Virios Said In Shareholder Letter, We Are Exploring Options To Advance The IMC-2 LC Investigational New Drug Application And Its Proposed Phase 2 Research Program
維里奧斯在股東信中表示，我們正在探索推進 IMC-2 LC 研究性新藥申請及其擬議的第二階段研究計劃的備選方案
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。